17beta-HSD5, 3-alpha hydroxysteroid dehydrogenase type 3, 3-alpha-HSD type 2, 3-alpha-HSD1, 3-alpha-hydroxysteroid dehydrogenase type 2, 3-alpha-hydroxysteroid dehydrogenase type I, 3alpha-HSD, 3alpha-HSD type III, 3alpha-HSD/CR, 3alpha-HSD3, 3alpha-HSOR, 3alpha-hydroxysteroid dehydrogenase, 3alpha-hydroxysteroid dehydrogenase type 3, 3alpha-hydroxysteroid dehydrogenase type III, 3alpha-hydroxysteroid dehydrogenase/carbonyl reductase, 3alpha-hydroxysteroid oxidoreductase, AKR1C1, AKR1C14, AKR1C2, AKR1C3, AKR1C33, AKR1C4, AKR1C9, aldo-keto reductase family 1 member C1, aldo-keto reductase family 1 member C2, aldo-keto reductase family 1 member C3, bile acid binding protein, chlordecone reductase, DD2, DD4, dihydrodiol dehydrogenase, dihydrodiol dehydrogenase 4, dihydrodiol/3alpha-hydroxysteroid dehydrogenase, HSD 28, HSD 29, hsdA, More, NADPH-dependent AKR1C9, Naloxone reductase 2, Ps3alphaHSD, type 1 3alpha-HSD, type 3 3alpha-hydroxysteroid dehydrogenase, type 5 17beta-hydroxysteroid dehydrogenase, type I 3alpha-HSD, type III 3-alpha-hydroxysteroid dehydrogenase
Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Microproteomics and Immunohistochemistry Reveal Differences in Aldo-Keto Reductase Family 1 Member C3 in Tissue Specimens of Ulcerative Colitis and Crohn's Disease.
Microproteomics and Immunohistochemistry Reveal Differences in Aldo-Keto Reductase Family 1 Member C3 in Tissue Specimens of Ulcerative Colitis and Crohn's Disease.
The role of the enterohepatic circulation of bile salts and nuclear hormone receptors in the regulation of cholesterol homeostasis: Bile salts as ligands for nuclear hormone receptors.
Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
Consecutive Prostate Cancer Specimens Revealed Increased Aldo?Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer.
Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?